葡萄膜黑色素瘤肝转移的区域化疗

Regional chemotherapy for uveal melanoma liver metastases.

作者信息

Tao Yang-Xu, Li Hao-Wen, Luo Jing-Ting, Li Yang, Wei Wen-Bin

机构信息

Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

出版信息

Int J Ophthalmol. 2023 Feb 18;16(2):293-300. doi: 10.18240/ijo.2023.02.18. eCollection 2023.

DOI:10.18240/ijo.2023.02.18

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9922637/

Abstract

Chemotherapy remains an important approach for the treatment of liver metastases from uveal melanoma (UM). Compared with systemic chemotherapy, regional chemotherapy has similar efficacy and fewer systemic adverse effects. Regional chemotherapy for UM liver metastases includes hepatic artery infusion (HAI), transarterial chemoembolization (TACE), and isolated hepatic perfusion (IHP). In this review, we aim to examine the efficacy of regional chemotherapy and compare HAI, TACE, and IHP in terms of overall survival (OS). The three approaches showed no obvious difference in OS results.

摘要

化疗仍然是治疗葡萄膜黑色素瘤（UM）肝转移的重要方法。与全身化疗相比，区域化疗疗效相似且全身不良反应较少。UM肝转移的区域化疗包括肝动脉灌注（HAI）、经动脉化疗栓塞（TACE）和孤立肝灌注（IHP）。在本综述中，我们旨在研究区域化疗的疗效，并比较HAI、TACE和IHP在总生存期（OS）方面的差异。这三种方法在OS结果上没有明显差异。

相似文献

1

Regional chemotherapy for uveal melanoma liver metastases.

Int J Ophthalmol. 2023 Feb 18;16(2):293-300. doi: 10.18240/ijo.2023.02.18. eCollection 2023.

2

Systematic review of liver directed therapy for uveal melanoma hepatic metastases.

HPB (Oxford). 2020 Apr;22(4):497-505. doi: 10.1016/j.hpb.2019.11.002. Epub 2019 Nov 30.

3

Survival and Quality of Life after Isolated Hepatic Perfusion with Melphalan as a Treatment for Uveal Melanoma Liver Metastases - Final Results from the Phase III Randomized Controlled Trial SCANDIUM.

Ann Surg. 2024 Feb 29. doi: 10.1097/SLA.0000000000006255.

4

Poor Response to Checkpoint Immunotherapy in Uveal Melanoma Highlights the Persistent Need for Innovative Regional Therapy Approaches to Manage Liver Metastases.

Cancers (Basel). 2021 Jul 8;13(14):3426. doi: 10.3390/cancers13143426.

5

Locoregional management of hepatic metastasis from primary uveal melanoma.

Semin Oncol. 2010 Apr;37(2):127-38. doi: 10.1053/j.seminoncol.2010.03.014.

6

Long-term survival in a patient with unresectable liver metastases from uveal melanoma treated with transarterial chemoembolization with irinotecan eluting beads - case report and review of literature.

Contemp Oncol (Pozn). 2017;21(3):244-248. doi: 10.5114/wo.2017.70115. Epub 2017 Sep 29.

7

Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study.

Eur J Surg Oncol. 2014 Nov;40(11):1557-63. doi: 10.1016/j.ejso.2014.06.010. Epub 2014 Jul 25.

8

Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study.

In Vivo. 2009 Jan-Feb;23(1):131-7.

9

Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit.

Ann Surg Oncol. 2014 Feb;21(2):466-72. doi: 10.1245/s10434-013-3304-z. Epub 2013 Oct 19.

10

Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases.

Cancers (Basel). 2021 Sep 21;13(18):4726. doi: 10.3390/cancers13184726.

引用本文的文献

1

An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.

Ann Surg Oncol. 2025 Apr 7. doi: 10.1245/s10434-025-17231-x.

本文引用的文献

1

Antibodies to watch in 2023.

MAbs. 2023 Jan-Dec;15(1):2153410. doi: 10.1080/19420862.2022.2153410.

2

Hepatic Artery Infusion Pumps: A Surgical Toolkit for Intraoperative Decision-Making and Management of Hepatic Artery Infusion-Specific Complications.

Ann Surg. 2022 Dec 1;276(6):943-956. doi: 10.1097/SLA.0000000000005434. Epub 2022 Mar 9.

3

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.

Nat Med. 2022 Nov;28(11):2364-2373. doi: 10.1038/s41591-022-02015-7. Epub 2022 Oct 13.

4

Treatment of metastatic uveal melanoma in 2022: improved treatment regimens and improved prognosis.

Curr Opin Ophthalmol. 2022 Nov 1;33(6):585-590. doi: 10.1097/ICU.0000000000000905. Epub 2022 Sep 8.

5

Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.

Cardiovasc Intervent Radiol. 2022 Sep;45(9):1304-1313. doi: 10.1007/s00270-022-03225-9. Epub 2022 Aug 3.

6

Recent Advances and Challenges in Uveal Melanoma Immunotherapy.

Cancers (Basel). 2022 Jun 23;14(13):3094. doi: 10.3390/cancers14133094.

7

Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.

J Clin Oncol. 2022 Jun 10;40(17):1939-1948. doi: 10.1200/JCO.21.01805. Epub 2022 Mar 7.

8

Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma.

Melanoma Res. 2022 Apr 1;32(2):103-111. doi: 10.1097/CMR.0000000000000806.

9

Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience.

Cancers (Basel). 2021 Dec 27;14(1):118. doi: 10.3390/cancers14010118.

10

Conventional Transarterial Chemoembolization Versus Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Cancers (Basel). 2021 Dec 7;13(24):6172. doi: 10.3390/cancers13246172.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。